15 Immunomodulation by mesenchymal stem cells – a potential therapeutic strategy for type 1 diabetes

Mounayar, Marwan; Magee, Ciara N.; Abdi, Reza

doi:10.1515/9783110298307.309

Cited by 2 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSCs can restrict insulin type 1 diabetes through collateral effect which has influence on nerve fiber role as well as gives anti-inflammatory action which could be imminent to continue outer endurance. They can be used to cure insulin dependent diabetes by altering the immunity as well as by examination of the process initially in mice while later in small scale studies in humans [73].…”

Section: Diabetesmentioning

confidence: 99%

Newer Advances in Mesenchymal Stem Cell Therapy

Kanase¹,

SHETTIGAR²

2020

Asian J Pharm Clin Res

View full text Add to dashboard Cite

In the modern world, overcoming diseases are more challenging and newer ways are being discovered to give high quality of patient care, on the basis of scientific experimentation and applicative studies undertaken by various institutes and organizations. Mesenchymal stem cells (MSCs) are procured through many body origins usually by the placenta as well as the umbilical cord but other sources like bone core derived MSCs are also important as each source will give the cells its own characteristic features. MSCs play a very important role in the scenario with their multi-lineage potency that can either directly or indirectly by acting on cytokines or growth factors can cause cell regeneration process and hold great possibility of wound repair, treating spinal cord injuries, and treating auto immune diseases by immunomodulation. MSCs can give incredible help in case of bone, cartilage or tissue related defects, injuries or disorders that may be corrected or repaired through it. They can be employed in various heart related complications, bacterial activity, sepsis, liver dysfunctions, diabetes, and even prove useful in cancer. Various procedures either physiological or surgical are present including cell therapies, tissue, and osteo-engineering and immune targeted experimentations that can treat the diseases as well as ensure complete recovery.

show abstract

Section: Diabetesmentioning

confidence: 99%

Newer Advances in Mesenchymal Stem Cell Therapy

Kanase¹,

SHETTIGAR²

2020

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

“…Taking advantage of their innate tropism for tumors, genetically engineered versions of MSC have been under preclinical and clinical development as cell delivery systems of several anticancer agents. One of the most commonly adopted approach is the enhancement of endogenous antitumor immunity by engineering MSC to produce antitumor cytokines or soluble factors such as β-interferon ( Ahn et al, 2013 ; Dembinski et al, 2013 ; Chen et al, 2019 ), interleukin-2 ( Mounayar et al, 2013 ; Zhao, 2013 ), interleukin-12 ( Elzaouk et al, 2006 ; Jeong et al, 2015 ), interleukin-15 ( Jing et al, 2014 ), INF-alpha ( Ren et al, 2008 ), or CX3CL1 ( Xin et al, 2007 ). Another approach is the use of MSC to deliver tumor cytotoxic agents such as TRAIL (TNF-α related apoptosis inducing ligand) ( Grisendi et al, 2010 ; Loebinger et al, 2010 ; Deng et al, 2014 ; Yan et al, 2014 ; Xia et al, 2015 ; Rossignoli et al, 2019 ; Spano et al, 2019 ), osteoprotegerin (OPG) ( Qiao et al, 2015 ), NK4 ( Kanehira et al, 2007 ), and HGF ( Zhu et al, 2009 ).…”

Section: Introductionmentioning

confidence: 99%

Conditioned Medium From Azurin-Expressing Human Mesenchymal Stromal Cells Demonstrates Antitumor Activity Against Breast and Lung Cancer Cell Lines

Silva

Monteiro

Fialho

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Recently, cell-based therapies have been explored as a strategy to enhance the specificity of anticancer therapeutic agents. In this perspective, human mesenchymal stromal cells (MSC) hold a promising future as cell delivery systems for anticancer proteins due to their unique biological features. In this study, we engineered human MSC to secrete a human codon-optimized version of azurin (hazu), a bacterial protein that has demonstrated anticancer activity toward different cancer models both in vitro and in vivo . To this end, microporation was used to deliver plasmid DNA encoding azurin into MSC derived from bone marrow (BM) and umbilical cord matrix (UCM), leading to expression and secretion of hazu to the conditioned medium (CM). Engineered hazu-MSC were shown to preserve tumor tropism toward breast (MCF-7) and lung (A549) cancer cell lines, comparable to non-modified MSC. Azurin was detected in the CM of transfected MSC and, upon treatment with hazu-MSC-CM, we observed a decrease in cancer cell proliferation, migration, and invasion, and an increase in cell death for both cancer cell lines. Moreover, expression of azurin caused no changes in MSC expression profile of cytokines relevant in the context of cancer progression, thus suggesting that the antitumoral effects induced by hazu-MSC secretome might be due to the presence of azurin independently. In conclusion, data shown herein indicate that MSC-produced azurin in a CM configuration elicits an anticancer effect.

show abstract

15 Immunomodulation by mesenchymal stem cells – a potential therapeutic strategy for type 1 diabetes

Cited by 2 publications

References 21 publications

Newer Advances in Mesenchymal Stem Cell Therapy

Newer Advances in Mesenchymal Stem Cell Therapy

Conditioned Medium From Azurin-Expressing Human Mesenchymal Stromal Cells Demonstrates Antitumor Activity Against Breast and Lung Cancer Cell Lines

Contact Info

Product

Resources

About